Shares of Ultragenyx Pharmaceutical (RARE) have risen by 37% since my January update recommended readers establish a pilot position and accumulate dips in the near term as a turnaround appeared likely.
Now that the stock has pulled back from highs last seen in April, I'm looking forward to revisiting to determine how our thesis has progressed and what opportunity exists for readers to take advantage of.
Chart
Figure 1: RARE daily advanced chart (Source: Finviz)
When looking at charts, clarity often comes from taking a look at distinct time frames in order to